May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Combined Use of Amniotic Membrane With Autologous Plasma Rich Growth Factors (P.R.G.F) in Corneal Regeneration
Author Affiliations & Notes
  • M. Abad
    R&i&i, VISSUM, Instituto Oftalmológico de Alicante, Alicante, Spain
  • J.L. Alió
    R&i&i, VISSUM, Instituto Oftalmológico de Alicante, Alicante, Spain
    Ophthalmology, Miguel Hernandez University, Elche (Alicante), Spain
  • J.L. Rodríguez–Prats
    R&i&i, VISSUM, Instituto Oftalmológico de Alicante, Alicante, Spain
  • Footnotes
    Commercial Relationships  M. Abad, None; J.L. Alió, None; J.L. Rodríguez–Prats, None.
  • Footnotes
    Support  Ministry of Science and Technology, Torres Quevedo Program (PTQ2003–0590)
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4982. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Abad, J.L. Alió, J.L. Rodríguez–Prats; Combined Use of Amniotic Membrane With Autologous Plasma Rich Growth Factors (P.R.G.F) in Corneal Regeneration . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4982.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Application of topical autologous plasma rich growth factors (P.R.G.F) combined with amniotic membrane transplantation to promote corneal tissue regeneration. Methods: In chronic corneal epithelium defects and acute corneal perforations, autologous P.R.G.F was used in combination with amniotic membrane transplantation. Growth factors released from the platelets include transforming beta type GF (TGF–ß), platelets derived GF (PDGF), epithelial GF (EGF), fibroblastic GF (FGF), endothelial vascular GF (VEGF) and insulin type 1 GF (IGF–1). These factors signal the local mesenchymal and epithelial cells to migrate, proliferate and differentiate restoring the ocular surface damages. The autologous blood was obtained by venipuncture and centrifuged. Concentrated platelets were activated by calcium chloride formating a clot that was applicated over the ocular defect followed by amniotic membrane transplantation. We used P.R.G.F eye drops for postsurgical treatment applied 6 times/day during 1 month. Results: 10 eyes were evaluated until epithelial wound closure. Patients were followed up for 1 year. A complete corneal re–epithelialization was achieved in 100% of cases. This novel therapy was found to be highly successful in severe corneal perforations. Conclusions: The combination of amniotic membrane transplantation with autologous P.R.G.F therapy leads to speeding healing up in cases of chronic corneal ulcers and acute corneal perforations. This novel and potentially promising technique can be considered as an effective and easy therapy without adverse events which stimulates tissue regeneration in pathologic conditions.

Keywords: cornea: clinical science • wound healing • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×